Quick Answer
Petros Pharmaceuticals, Inc. reported Operating Income Loss of -$17.68 million for the year ending 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -29.8% in Operating Income Loss from 2023 to 2024.
- This data is from Petros Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$5.61 million | Q2 2020: -$5.02 million | Q3 2020: -$2.34 million | Q1 2021: -$2.20 million | Q2 2021: -$4.28 million | Q3 2021: -$3.60 million | Q1 2022: -$481.2 thousand | Q2 2022: -$1.66 million | Q3 2022: -$13.67 million | Q1 2023: -$1.31 million | Q2 2023: -$2.46 million | Q3 2023: -$4.81 million | Q1 2024: -$1.50 million | Q2 2024: -$1.35 million | Q3 2024: -$1.20 million | Q1 2025: -$1.46 million | Q2 2025: -$1.80 million | Q3 2025: -$990.7 thousand.
- Over the full 5 years of available data (2020 to 2024), Petros Pharmaceuticals, Inc.'s Operating Income Loss has declined by 2.3%.
- Historical annual values: Fiscal year 2024: -$17.68 million | Fiscal year 2023: -$13.62 million | Fiscal year 2022: -$19.92 million | Fiscal year 2021: -$18.05 million | Fiscal year 2020: -$17.28 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: